Pentixapharm Holding AG is a Germany-based clinical-stage radiopharmaceutical development company. The Company focuses on the development of radiopharmaceuticals for various therapeutic areas, as well as for the diagnosis and therapy (theranostics) of blood cancer and others. It is also engaged in holding activities and is also involved in the research and development of drugs for hematological and solid cancers, as well as cardiovascular, endocrine and inflammatory diseases.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
07/10/26	€1.845	-0.27%	10,263
06/10/26	€1.850	0.00%	478
05/10/26	€1.850	+1.37%	2,709
02/10/26	€1.825	-1.35%	8,854
01/10/26	€1.850	0.00%	3,126

Delayed Quote Xetra

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.845EUR

Average target price

9.265EUR

Spread / Average Target

+402.17%

Consensus

EPS Estimates

Evolution of Analysts' Estimates - EPS - Pentixapharm Holding AG

Revisions to estimates

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Pentixapharm Holding AG

Company calendar

Market Closed - Xetra 16:35:43 07/10/2026 BST			5-day change	1st Jan Change
1.845 ^EUR	-0.27%		-0.27%	+24.49%

10-05	German Watchdog Finds Errors in Pentixapharm's FY24 Financial Statements	MT
08-06	Pentixapharm Holding AG Reports Earnings Results for the Half Year Ended June 30, 2026	CI

Market Cap	45.72M 51.17M 42.66M 38.75M 72.98M 4.95B 73.52M 513M 200M 2.52B 192M 188M 8.09B	P/E 2026 *	-2.98x	P/E 2027 *	-2.8x
Enterprise Value	38.42M 43M 35.85M 32.56M 61.33M 4.16B 61.78M 431M 168M 2.12B 161M 158M 6.8B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	68.98%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Xetra	PTP	Delayed
Tradegate	PTP	Real-time
Börse Stuttgart	PTP	Delayed
Boerse Muenchen	PTP	Real-time
CBOE		Real-time
Deutsche Boerse AG	PTP	Delayed
CBOE		Real-time
Wiener Boerse	PTPN	End-of-day quote

10-05	German Watchdog Finds Errors in Pentixapharm's FY24 Financial Statements	MT
08-06	Pentixapharm Holding AG Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-06	Pentixapharm Holding AG and Pentixapharm AG Announce Executive Changes	CI
08-06	Pentixapharm Holding Ag Reaffirms Earnings Guidance for the Full Year 2026	CI
07-22	Pentixapharm Raises EUR16.8 Million via Rights Offering	MT
07-22	Eckert & Ziegler: BaFin reviews 2024 financial statements over Pentixapharm spin-off	DP
07-22	Eckert & Ziegler next in BaFin's sights, shares rebound	DP
07-22	Eckert & Ziegler Faces BaFin Review Over Pentixapharm Spin-off Accounting	MT
07-22	Eckert & Ziegler: BaFin reviews 2024 financial statements over Pentixapharm spin-off	DP
07-09	Pentixapharm Holding AG Receives FDA Fast Track Designation For Phase 3 Diagnostic Candidate [68Ga]Ga-Pentixafor In Primary Aldosteronism	CI
07-09	Pentixapharm's Underdevelopment Radiodiagnostic Gets Fast Track Designation From US FDA	MT
06-09	Pentixapharm Disputes German Regulator's Preliminary Error Findings in FY24 Financial Statements	MT
06-09	Pentixapharm Holding Ag Announces Fda Clearance of Ind for Phase 3 Panda Study of First-In-Class Cardiovascular Diagnostic Program	CI

Pentixapharm Holding AG Share Price

Stocks

PTP

DE000A40AEG0

Pharmaceuticals

Valuation: Pentixapharm Holding AG

Chart: Pentixapharm Holding AG

Latest news: Pentixapharm Holding AG

Press Releases: Pentixapharm Holding AG

News in other languages: Pentixapharm Holding AG

Quotes and Performance

Price Extremes

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Analysts' Consensus

Annual profits - Rate of surprise

10-02	Pentixapharm Holding AG: Bafin concludes financial reporting review of the 2024 consolidated financial statements with an error finding	EQ
08-17	Pentixapharm Holding AG: Eckert Wagniskapital und Frühphasenfinanzierung GmbH, Purchase of shares by exercising subscription rights	EQ
08-06	Pentixapharm Reports Second Quarter and First Half 2026 Results and Advances Phase 3 Panda Program	EQ
07-27	Pentixapharm Completes Capital Increase – New Shares Placed in Full	EQ
07-27	Pentixapharm Holding AG completes rights offering and private placement with significant oversubscription generating gross proceeds of approx. EUR 20.4 Million already today	EQ

10-02	Pentixapharm Holding AG: Bafin schließt Bilanzkontrolle des Konzernabschlusses 2024 mit Fehlerfeststellung ab
08-17	Pentixapharm Holding AG: Eckert Wagniskapital und Frühphasenfinanzierung GmbH, Erwerb von Aktien durch Ausübung von Bezugsrechten
08-06	Pentixapharm veröffentlicht Ergebnisse für das zweite Quartal und das erste Halbjahr 2026 und treibt das Phase-3-PANDA-Programm voran
08-06	Pentixapharm : veröffentlicht Ergebnisse für das zweite Quartal und das erste Halbjahr 2026 und treibt das Phase-3-PANDA-Programm voran
08-04	Pentixapharm Holding AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung

1 day	-0.27%
1 week	-0.27%
Current month	-0.27%
1 month	-3.15%
3 months	-12.14%
6 months	-9.56%
Current year	+24.49%

1 week	1.82	1.89
1 month	1.82	1.92
Current year	1.48	3.7
1 year	1.3	3.7
3 years	1.3	5.15
5 years	1.3	5.15
10 years	1.3	5.15

Date	Insider	Type	Main position	Quantity	% Market Cap.
30/07/26	Andreas Eckert	Exercice	Chairman	3,965,539	11.0721%
07/07/26	Andreas Eckert	Free	Chairman	8,922,464	35.9842%
27/11/25	Andreas Eckert	Buy	Chairman	70,924	0.2860%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PENTIXAPHARM HOLDING AG	-0.27%	-0.27%	+1.37%	-	51.17M
ELI LILLY AND COMPANY	+2.70%	+2.73%	+40.91%	+110.31%	1,060B
JOHNSON & JOHNSON	+1.44%	-2.38%	+36.83%	+63.95%	623B
ABBVIE INC.	+1.75%	+3.73%	+16.55%	+83.05%	480B
MERCK & CO., INC.	+0.60%	-1.73%	+62.98%	+37.46%	352B
ROCHE HOLDING AG	+2.92%	+3.12%	+24.78%	+45.10%	345B
NOVARTIS AG	+2.42%	+0.05%	+14.13%	+35.80%	274B
ASTRAZENECA PLC	+1.86%	-0.81%	-4.69%	+12.20%	249B
AMGEN INC.	+2.60%	-2.00%	+39.77%	+54.44%	223B
GILEAD SCIENCES, INC.	+1.82%	-1.48%	+25.75%	+96.48%	182B
Average	+1.28%	-1.08%	+25.84%	+59.87%	378.81B
Weighted average by Cap.	+0.81%	-0.46%	+32.00%	+70.72%

	2026 *	2027 *
Net sales	-	-
Net income	-22.3M -24.96M -20.81M -18.9M -35.59M -2.41B -35.86M -250M -97.68M -1.23B -93.7M -91.67M -3.95B	-23.5M -26.3M -21.92M -19.91M -37.51M -2.54B -37.79M -263M -103M -1.29B -98.74M -96.6M -4.16B
Net Debt	-7.3M -8.17M -6.81M -6.19M -11.65M -790M -11.74M -81.84M -31.97M -402M -30.67M -30.01M -1.29B	12.3M 13.77M 11.48M 10.42M 19.63M 1.33B 19.78M 138M 53.87M 677M 51.68M 50.56M 2.18B